<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-164817" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Heart Failure With Preserved Ejection Fraction (HFpEF)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Golla</surname>
            <given-names>Maheswara Satya G.</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shams</surname>
            <given-names>Pirbhat</given-names>
          </name>
          <aff>The Aga Khan University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maheswara Satya Golla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pirbhat Shams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-164817.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Heart failure is a clinical syndrome resulting from complex pathophysiological processes that impair ventricular structure or function. These impairments prohibit the ventricle from either filling with or ejecting blood.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;The signs and symptoms of heart failure, particularly dyspnea, fatigue, and congestion, are demonstrative of the most current definition of heart failure&#x02014;"an inability of the heart to pump blood to the body commensurate with its needs, or to so do only at the cost of increased filling pressures."<xref ref-type="bibr" rid="article-164817.r1">[1]</xref><xref ref-type="bibr" rid="article-164817.r2">[2]</xref></p>
        <p>Heart failure is a significant public health issue; the incidence and prevalence of heart failure are increasing in the United States and across the globe. Additionally, heart failure is the end stage of many disease processes, and the risk of developing heart failure increases with increasing age.<xref ref-type="bibr" rid="article-164817.r3">[3]</xref>&#x000a0;Heart failure is frequently a progressive disease process, and progression is associated with decreased survival, regardless of underlying etiology.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref><xref ref-type="bibr" rid="article-164817.r4">[4]</xref>&#x000a0;To underline these risks and the progression of disease, the American College of Cardiology and American Heart Association (ACC/AHA) have described and defined the following stages of heart failure:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage A: At Risk for Heart Failure</bold> - patients at risk for heart failure without symptoms, structural heart disease, or cardiac biomarkers of (ventricular) stretch or injury. Therapeutic interventions at this stage aim to modify underlying risk factors for the development of heart failure.</p>
          </list-item>
          <list-item>
            <p><bold>Stage B: Pre-Heart Failure</bold> - patients with evidence of increased filling pressures by invasive or noninvasive methods or patients with risk factors and increased biomarkers of stretch or cardiac injury that are not explained by other disease processes. Therapeutic interventions at this stage aim to treat risk and structural heart disease to prevent heart failure.</p>
          </list-item>
          <list-item>
            <p><bold>Stage C: Symptomatic Heart Failure</bold> - patients with structural heart disease with current or previous symptoms of heart failure. Therapeutic interventions at this stage aim to reduce symptoms, morbidity, and mortality.</p>
          </list-item>
          <list-item>
            <p><bold>Stage D: Advanced Heart Failure</bold> - patients with marked symptoms of heart failure that interfere with daily life and with recurrent hospitalizations despite attempts to optimize guideline-directed medical therapy. Therapeutic interventions at this stage aim to reduce symptoms, morbidity, and mortality.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Separate from the ACC/AHA Stage of Heart Failure is the New York Heart Association (NYHA) Classification of Heart Failure. This classification is a subjective assessment by a clinician to characterize the functional capacity and symptoms of patients with ACC/AHA stage C or D heart failure.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;The NYHA Classification is an independent predictor of mortality and is employed clinically to determine the suitability of therapeutic interventions for patients with stage C or D heart failure.<xref ref-type="bibr" rid="article-164817.r5">[5]</xref><xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;The 4 NYHA heart failure classes are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Class I</bold>: asymptomatic</p>
          </list-item>
          <list-item>
            <p><bold>Class II</bold>: symptomatic with moderate activity</p>
          </list-item>
          <list-item>
            <p><bold>Class III</bold>: symptomatic with mild activity</p>
          </list-item>
          <list-item>
            <p><bold>Class IV</bold>: symptomatic at rest.</p>
          </list-item>
        </list>
        <p>Heart failure is further classified by left ventricular ejection fraction (LVEF).<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;The prognosis and response to treatment of patients with heart failure differs significantly when patients are stratified based on LVEF. In 2022, the ACC, AHA, and Heart Failure Society of America (HFSA) released guidelines for the management of heart failure that incorporate the following classification of heart failure by LVEF:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Heart Failure with Reduced Ejection Fraction (HFrEF)</bold>: patients with an LVEF&#x000a0;&#x02264;40%</p>
          </list-item>
          <list-item>
            <p><bold>Heart Failure with Improved Ejection Fraction (HFimpEF)</bold>: patients with a previous LVEF &#x02264;40% and a subsequent measurement of LVEF &#x0003e;40%</p>
          </list-item>
          <list-item>
            <p><bold>Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)</bold>: patients with an LVEF 41% to 49% with evidence of spontaneous or provokable increased left ventricular filling pressures (LVFPs), characterized by elevated natriuretic peptides or hemodynamic measurements. HFmrEF is sometimes referred to as heart failure with midrange ejection fraction in the literature.</p>
          </list-item>
          <list-item>
            <p><bold>Heart Failure with Preserved Ejection Fraction (HFpEF)</bold>: patients with an LVEF&#x000a0;&#x02265;50% with evidence of spontaneous or provokable increased left ventricular filling pressures (LVFPs), characterized by elevated natriuretic peptides or hemodynamic measurements.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>The diagnosis of HFpEF can be challenging, particularly in patients with overt signs or symptoms of congestion.<xref ref-type="bibr" rid="article-164817.r6">[6]</xref>&#x000a0;However, approximately 50% of patients with heart failure are classified as HFpEF;&#x000a0;not all patients with HFpEF will progress to HFrEF.<xref ref-type="bibr" rid="article-164817.r7">[7]</xref><xref ref-type="bibr" rid="article-164817.r8">[8]</xref>&#x000a0;HFpEF is a heterogeneous clinical syndrome with many phenotypes, and the underlying pathophysiological processes of HFpEF differ from those of HFrEF.<xref ref-type="bibr" rid="article-164817.r9">[9]</xref><xref ref-type="bibr" rid="article-164817.r10">[10]</xref>&#x000a0;While all patients with heart failure have ventricular diastolic dysfunction, diastolic dysfunction is considered part of the normal again process and is not synonymous with HFpEF.<xref ref-type="bibr" rid="article-164817.r11">[11]</xref></p>
        <p>Patients with HFpEF have increased rates of morbidity and mortality compared to patients without heart failure.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;However, therapeutic interventions are available to reduce symptoms, improve functional status and quality of life, and reduce hospital admission rates.<xref ref-type="bibr" rid="article-164817.r12">[12]</xref>&#x000a0;Clinical understanding of HFpEF continues to evolve, and clinical trials to improve outcomes for patients with HFpEF are ongoing.</p>
      </sec>
      <sec id="article-164817.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Heart failure is the common endpoint for many disease processes.<xref ref-type="bibr" rid="article-164817.r3">[3]</xref> Worldwide, the most common underlying etiology of heart failure is ischemic heart disease secondary to coronary artery disease, which confers a relative risk of heart failure of 8.1.<xref ref-type="bibr" rid="article-164817.r13">[13]</xref>&#x000a0;Independent risk factors for the development of heart failure as identified during the First National Health and Nutrition Examination Survey (NHANES I) Epidemiologic Follow-up Study include male sex, cigarette smoking, overweight/obesity, diabetes, hypertension, and valvular disease.<xref ref-type="bibr" rid="article-164817.r13">[13]</xref>&#x000a0;Social determinants of health, such as education, occupation, and income, also contribute to the development of heart failure.<xref ref-type="bibr" rid="article-164817.r14">[14]</xref><xref ref-type="bibr" rid="article-164817.r15">[15]</xref></p>
        <p>
<bold>Predisposing Conditions for Primary Heart Failure With Preserved Ejection Fraction</bold>
</p>
        <p>The risk factors, underlying etiologies, and pathophysiology of HFpEF and HFrEF differ significantly; HFpEF is a heterogeneous clinical syndrome.<xref ref-type="bibr" rid="article-164817.r16">[16]</xref>&#x000a0;Increasing&#x000a0;age is the most significant risk factor for&#x000a0;all heart failure subtypes; aging significantly influences the development of HFpEF more than HFrEF.<xref ref-type="bibr" rid="article-164817.r17">[17]</xref><xref ref-type="bibr" rid="article-164817.r18">[18]</xref>&#x000a0;However, individuals younger than 65 can develop HFpEF; this may represent a unique age-based phenotype.<xref ref-type="bibr" rid="article-164817.r9">[9]</xref></p>
        <p>This same increased influence is seen for atrial fibrillation, female sex, and pulmonary hypertension of any etiology.<xref ref-type="bibr" rid="article-164817.r18">[18]</xref>&#x000a0;Obesity and diabetes are also significant risk factors and predictors of HFpEF.<xref ref-type="bibr" rid="article-164817.r18">[18]</xref>&#x000a0;Patients with HFpEF and obesity tend to be younger than patients with HFpEF and an average body mass index.<xref ref-type="bibr" rid="article-164817.r19">[19]</xref>&#x000a0;While arterial hypertension is a significant risk factor for the development of HFpEF across all populations, obesity is a disproportionately substantial risk factor for patients who identify as African American or Hispanic.<xref ref-type="bibr" rid="article-164817.r20">[20]</xref></p>
        <p>HFpEF is rarely due to a single identifiable clinical condition but arises in patients with various risk factors; the predominant risk factor may or may not indicate a specific phenotype of HFpEF&#x02014;thus, the heterogeneity of the disease.<xref ref-type="bibr" rid="article-164817.r16">[16]</xref>&#x000a0;Risk factors for the development of HFpEF appear to include but are not limited to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Increasing age</p>
          </list-item>
          <list-item>
            <p>Female sex</p>
          </list-item>
          <list-item>
            <p>Type 2 diabetes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Obesity</p>
          </list-item>
          <list-item>
            <p>Sleep apnea</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Pulmonary hypertension</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Iron deficiency, with or without anemia</p>
          </list-item>
          <list-item>
            <p>Coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation</p>
          </list-item>
          <list-item>
            <p>Dysrhythmias&#x000a0;<xref ref-type="bibr" rid="article-164817.r16">[16]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The exact pathogenic role of each risk factor is poorly understood.</p>
        <p>
<bold>Etiologies of Secondary Heart Failure With Preserved Ejection Fraction</bold>
</p>
        <p>Secondary HFpEF occurs in a clinical condition that directly causes the heart to fail. These conditions are sometimes referred to as "HFpEF mimics."<xref ref-type="bibr" rid="article-164817.r16">[16]</xref>&#x000a0;These mimics include but are not limited to restrictive and hypertrophic cardiomyopathies of any etiology, constrictive pericarditis, and valvular heart disease.<xref ref-type="bibr" rid="article-164817.r16">[16]</xref><xref ref-type="bibr" rid="article-164817.r7">[7]</xref>&#x000a0;In the United States, left-sided valvular disease is the most commonly encountered HFpEF mimic, and aortic stenosis should be suspected in all patients with signs, symptoms, or suspicion of HFpEF.<xref ref-type="bibr" rid="article-164817.r21">[21]</xref><xref ref-type="bibr" rid="article-164817.r16">[16]</xref></p>
        <p>
<bold>Etiologies of Acute Decompensation of Heart Failure With Preserved Ejection Fraction</bold>
</p>
        <p>Patients with HFpEF are at increased risk for deterioration of cardiac function in the setting of various commonly encountered clinical conditions. The development of a clinical condition requiring increased cardiac output that the failing heart cannot meet increases the risk of acute pulmonary and systemic venous congestion.<xref ref-type="bibr" rid="article-164817.r22">[22]</xref>&#x000a0;Examples of cardiovascular and noncardiovascular conditions that may induce the acute decompensation of patients with HFpEF include but are not limited to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute kidney injury or worsening chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Chronic pulmonary disease, or the exacerbation thereof</p>
          </list-item>
          <list-item>
            <p>Dysrhythmia, particularly tachyarrhythmia, especially new-onset atrial fibrillation</p>
          </list-item>
          <list-item>
            <p>Infection</p>
          </list-item>
          <list-item>
            <p>Ischemia</p>
          </list-item>
          <list-item>
            <p>Increased salt intake or water retention</p>
          </list-item>
          <list-item>
            <p>Medication noncompliance, including antihypertensive or diuretics</p>
          </list-item>
          <list-item>
            <p>Poorly controlled or uncontrolled hypertension.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-164817.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Heart failure is a significant public health issue in the United States and globally. Worldwide estimates for individuals living with heart failure exceed 60 million people, equating to a prevalence of 1% to 3% of the global population.<xref ref-type="bibr" rid="article-164817.r17">[17]</xref> Heart failure is the most common reason for hospitalization for patients 65 and older in the United States, and rates of hospitalizations increased from 2014 to 2017.<xref ref-type="bibr" rid="article-164817.r23">[23]</xref>&#x000a0;Approximately 6.7 million Americans older than 25 are estimated to have some form of heart failure; this number is expected to increase to 8.5 million Americans by 2030.<xref ref-type="bibr" rid="article-164817.r23">[23]</xref>&#x000a0;The incidence and prevalence of heart failure increase with age.<xref ref-type="bibr" rid="article-164817.r17">[17]</xref>&#x000a0;The lifetime risk of heart failure has increased from approximately 20% to 24%, possibly due to an increase in life expectancy and the incidence of comorbidities such as hypertension, diabetes, and obesity.<xref ref-type="bibr" rid="article-164817.r24">[24]</xref></p>
        <p>Data gathered from the second 25-year epoch of the Framingham Heart Study (1990-2014) has demonstrated that the lifetime risk of HFpEF approximates 19.3%, exceeding the approximate 11.4% lifetime risk of HFrEF.<xref ref-type="bibr" rid="article-164817.r23">[23]</xref><xref ref-type="bibr" rid="article-164817.r24">[24]</xref>&#x000a0;This appears to be particularly true for women, whose apparent lifetime risk of HFpEF is 10.7% compared to 5.8% for HFrEF; these risks vary with ethnicity.<xref ref-type="bibr" rid="article-164817.r25">[25]</xref><xref ref-type="bibr" rid="article-164817.r26">[26]</xref>&#x000a0;</p>
        <p>The incidence and prevalence of HFpEF varies among populations and is increasing overall; this increase may partially be due to improved diagnostic capabilities and more uniform diagnostic parameters. Tsao et al. reported an increase of 53% in HFpEF diagnoses among participants in the Framingham Heart Study and Cardiovascular Health Study between 2000 and 2009.<xref ref-type="bibr" rid="article-164817.r27">[27]</xref>&#x000a0;Chang et al. reported an 8.2% increase in HFpEF diagnoses among Black women compared to a 5.9% increase for White women; all patients participated in the Atherosclerosis Risk in Communities Study between 2005 and 2014.<xref ref-type="bibr" rid="article-164817.r26">[26]</xref>&#x000a0;The same study demonstrated a rise in HFpEF diagnoses for Black men (5.7%) and White men (6.3%).<xref ref-type="bibr" rid="article-164817.r26">[26]</xref>&#x000a0;Contrarily, data derived from Olmstead County in Minnesota demonstrated a decrease of 28% in the incidence of HFpEF diagnoses between 2000 and 2010.<xref ref-type="bibr" rid="article-164817.r23">[23]</xref></p>
        <p>While it is clear that the overall prevalence of heart failure is increasing globally, the incidence and prevalence of heart failure demonstrate significant geographic differences. However, data&#x000a0;are lacking from some geographic areas, such as Sub-Saharan Africa, and differences in diagnostic criteria and reporting practices across the globe limit the accuracy of comparative data. Despite these limitations, when available data&#x000a0;are derived from studies that define HFpEF as an ejection fraction of&#x000a0;&#x02265;50%, stark geographic differences in prevalence emerge.&#x000a0;Shiga et al. reported an HFpEF prevalence of 43% in 1245 patients with heart failure hospitalized in Japan between 2013 and 2014.<xref ref-type="bibr" rid="article-164817.r28">[28]</xref>&#x000a0;Wang et al. evaluated 5236 patients in a community-based heart failure management program in Australia and reported a 37.4% prevalence&#x000a0;of HFpEF diagnoses.<xref ref-type="bibr" rid="article-164817.r29">[29]</xref>&#x000a0;In contrast, the prevalence of HFpEF diagnoses in the European Society of Cardiology long-term registry and Asian Sudden Cardiac Death in Heart Failure Registry was only 16%.<xref ref-type="bibr" rid="article-164817.r30">[30]</xref></p>
      </sec>
      <sec id="article-164817.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The clinical manifestations of HFpEF are ultimately due to complex pathophysiological processes in cardiomyocyte structure and function, resulting&#x000a0;in hemodynamic derangements.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref>&#x000a0;However, the pathophysiology of HFpEF is likely not limited to the cardiomyocyte (see <bold>Image.</bold> Pathophysiology of Heart Failure).</p>
        <p>Obesity is a major risk factor for the development of HFpEF.<xref ref-type="bibr" rid="article-164817.r31">[31]</xref>&#x000a0;Obesity is a chronic systemic inflammatory state that induces hemodynamic derangements and hormonal abnormalities that stress the cardiovascular system.<xref ref-type="bibr" rid="article-164817.r32">[32]</xref>&#x000a0;Overweight and obese individuals demonstrate subclinical changes in the structure and function of the left ventricle, even in the presence of a normal ejection fraction.<xref ref-type="bibr" rid="article-164817.r33">[33]</xref>&#x000a0;Increased adiposity is associated with worsening left ventricular diastolic function regardless of left ventricular mass.<xref ref-type="bibr" rid="article-164817.r34">[34]</xref>&#x000a0;Central obesity is associated with age-related increases in ventricular end-systolic elastance in women but not in men; obesity and female sex are significant risk factors for the development of HFpEF.<xref ref-type="bibr" rid="article-164817.r35">[35]</xref>&#x000a0;Additionally, right ventricular function is impaired in patients with HFpEF; right ventricular dysfunction is more&#x000a0;marked in obese patients with HFpEF than in those with a normal body mass index.<xref ref-type="bibr" rid="article-164817.r36">[36]</xref><xref ref-type="bibr" rid="article-164817.r37">[37]</xref><xref ref-type="bibr" rid="article-164817.r38">[38]</xref></p>
        <p>Integral to the pathophysiology of HFpEF is the concept of diminished&#x000a0;physiologic reserve.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref>&#x000a0;Abnormalities in skeletal muscle and vascular endothelium significantly contribute to decreased reserve. Exercise tolerance and capacity are decreased in patients with HFpEF, as demonstrated by more severe dyspnea and fatigue at matched workloads than controls.<xref ref-type="bibr" rid="article-164817.r39">[39]</xref>&#x000a0;This appears particularly true in older patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r40">[40]</xref><xref ref-type="bibr" rid="article-164817.r41">[41]</xref>&#x000a0;Additionally, patients with HFpEF demonstrate impaired peripheral oxygen extraction during exercise; the exact etiology of this impairment remains undefined but may represent intrinsic deficiencies in the function of skeletal muscle, vascular endothelium, or mitochondria.<xref ref-type="bibr" rid="article-164817.r42">[42]</xref><xref ref-type="bibr" rid="article-164817.r43">[43]</xref>&#x000a0;Patients with HFpEF demonstrate a reduction in total arterial compliance during submaximal and peak exercise.<xref ref-type="bibr" rid="article-164817.r44">[44]</xref>&#x000a0;While oxygen transport and utilization are impaired in all patients with HFpEF regardless of the degree of exercise intolerance, exact impairments vary among&#x000a0;patients, and underlying comorbidities strongly influence impairment.<xref ref-type="bibr" rid="article-164817.r45">[45]</xref><xref ref-type="bibr" rid="article-164817.r42">[42]</xref></p>
        <p>While the cellular mechanisms contributing to HFpEF remain ill-defined, the result of cellular and tissue pathophysiologic processes is structural remodeling of the left ventricle, a subsequent decrease in left ventricular reserve, abnormal hemodynamics, and the secondary organ dysfunction that causes the clinical syndrome of HFpEF.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref> Historically, HFpEF was thought to present in patients with concentric ventricular remodeling; recent studies have demonstrated that HFpEF may be&#x000a0;observed&#x000a0;in patients with any form of cardiac remodeling, and many patients with HFpEF have normal ventricular structure.<xref ref-type="bibr" rid="article-164817.r46">[46]</xref></p>
        <p>Despite the heterogeneity of left ventricular structure, the most prominent hemodynamic finding in patients with HFpEF is elevated LVFPs.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref>&#x000a0;Patients in the early stages of HFpEF have normal LVFPs at rest, and elevations only occur with exercise.<xref ref-type="bibr" rid="article-164817.r47">[47]</xref><xref ref-type="bibr" rid="article-164817.r39">[39]</xref>&#x000a0;As the disease progresses, elevations in LVFPs are&#x000a0;observed at rest.<xref ref-type="bibr" rid="article-164817.r39">[39]</xref>&#x000a0;These elevations in LVFPs are the result of left ventricular diastolic dysfunction secondary to incomplete myocardial relaxation, increased ventricular stiffness with subsequent decreased ventricular distensibility, and a shift in the Frank-Starling mechanism initially during exercise and eventually at rest.<xref ref-type="bibr" rid="article-164817.r48">[48]</xref><xref ref-type="bibr" rid="article-164817.r49">[49]</xref><xref ref-type="bibr" rid="article-164817.r50">[50]</xref></p>
        <p>Elevations in LVFPs, even when inconsistent, induce structural remodeling of the left atrium. Significant differences in left atrial structure and function exist between patients with HFpEF and those with HFrEF; left atrial function is more closely correlated with outcomes in HFpEF.<xref ref-type="bibr" rid="article-164817.r10">[10]</xref>&#x000a0;Compared to patients with HFrEF, patients with HFpEF have smaller left atrial volumes. However, patients with HFpEF&#x000a0;have increased left atrial peak pressures, stiffness, and wall stress and are more likely to have atrial fibrillation.<xref ref-type="bibr" rid="article-164817.r10">[10]</xref>&#x000a0;Atrial fibrillation further exacerbates the remodeling and dysfunction of the left atrium, which increases the risk of pulmonary hypertension.<xref ref-type="bibr" rid="article-164817.r51">[51]</xref>&#x000a0;The development of pulmonary hypertension significantly increases the risk of death in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r52">[52]</xref></p>
        <p>The development of pulmonary hypertension increases right ventricular dysfunction, and this phenomenon is increased in patients with obesity who are already at increased risk of right ventricular dysfunction.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref>&#x000a0;Right ventricular dysfunction significantly increases the risk of death in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r36">[36]</xref><xref ref-type="bibr" rid="article-164817.r53">[53]</xref></p>
        <p>Ultimately, it is this constellation of dysfunctional&#x000a0;processes at the cellular, tissue, and organ levels that causes the clinical constellation of signs and symptoms&#x000a0;observed in patients with HFpEF, namely exertional dyspnea progressing to dyspnea at rest, fatigue, decreased organ perfusion, pulmonary congestion, and edema.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-164817.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Endomyocardial biopsy is neither required nor routinely recommended when diagnosing or managing chronic HFpEF. However, multiple studies have suggested that, unlike the myocardial remodeling in HFrEF driven by cardiomyocyte loss, cardiac remodeling in HFpEF may stem from coronary microvascular inflammation and deranged intramyocardial signaling.<xref ref-type="bibr" rid="article-164817.r54">[54]</xref>&#x000a0;The myocardium of patients with HFpEF demonstrates upregulated E-selectins and intercellular adhesion molecule-1 expression, which may contribute to cardiomyocyte hypertrophy and stiffness.<xref ref-type="bibr" rid="article-164817.r55">[55]</xref>&#x000a0;Cardiomyocytes from patients with HFpEF demonstrate increased levels of collagen and titin, which may also contribute to ventricular stiffness.<xref ref-type="bibr" rid="article-164817.r56">[56]</xref>&#x000a0;Canine studies have demonstrated that increased phosphorylation of titin improves ventricular diastolic distensibility.<xref ref-type="bibr" rid="article-164817.r57">[57]</xref></p>
      </sec>
      <sec id="article-164817.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with HFpEF typically exhibit intolerance to physical activity characterized by exertional dyspnea (98%) and fatigue (59%).<xref ref-type="bibr" rid="article-164817.r2">[2]</xref><xref ref-type="bibr" rid="article-164817.r58">[58]</xref>&#x000a0;With the progression of HFpEF, these symptoms will occur with lower activity levels and may be accompanied by evidence of congestion.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref><xref ref-type="bibr" rid="article-164817.r58">[58]</xref>&#x000a0;Some patients with HFpEF are clinically asymptomatic, or their symptoms are so mild&#x000a0;they go unnoticed.</p>
        <p>The remaining clinical manifestations of HFpEF are typically the same as seen in other heart failure subtypes, including HFrEF. Obtaining a thorough medical history and performing a comprehensive physical examination facilitate the classification of heart failure, which helps guide therapeutic interventions. The signs and symptoms of heart failure overlap with many other disease processes. Worsening ventricular dysfunction results in more severe symptoms and apparent signs. However, there is no single sign or symptom pathognomonic for heart failure.</p>
        <p>
<bold>Medical History</bold>
</p>
        <p>A comprehensive medical history should include a thorough medication history, including patient medication compliance. Inquiries into cardiovascular risk factors, known cardiovascular diagnoses, and prior cardiovascular interventions are mandatory. Any family history of heart failure in the 3 previous generations should be noted; many cardiomyopathies have a genetic component. Quantification of current and prior tobacco and alcohol use, as well as any history of exposure to drugs of abuse, must be pursued. An assessment of social determinants of health is recommended.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref></p>
        <p>Symptoms that patients with heart failure commonly describe include dyspnea, initially with exertion and then at rest. Patients may describe orthopnea or paroxysmal nocturnal dyspnea.<xref ref-type="bibr" rid="article-164817.r2">[2]</xref><xref ref-type="bibr" rid="article-164817.r58">[58]</xref>&#x000a0;Dulled mental status or "brain fog" is not uncommon. Daytime oliguria with resulting nocturia is regularly seen as extravasation of vascular fluid worsens. Peripheral edema of the distal lower extremities may initially resolve with elevation; patients commonly report going to bed with swollen feet that normalize by morning. Eventually, this edema may become pitting. Right upper quadrant pain is sometimes reported and is evidence of liver capsular distention. Anorexia and nausea may be evidence of decreased perfusion of the bowel and bowel edema.<xref ref-type="bibr" rid="article-164817.r59">[59]</xref>&#x000a0;Exertional chest pain is also a common presenting symptom.<xref ref-type="bibr" rid="article-164817.r59">[59]</xref></p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Physical examination findings vary with the severity of the heart failure. Patients with isolated HFpEF who are not acutely decompensated are most likely to demonstrate mild systolic hypertension, and approximately 10% to 20% have some degree of jugular venous distention.<xref ref-type="bibr" rid="article-164817.r58">[58]</xref></p>
        <p>Evidence of diaphoresis, tachycardia, tachypnea, and hypoxia are indicative of severe heart failure or acute decompensation.<xref ref-type="bibr" rid="article-164817.r59">[59]</xref>&#x000a0;Contrarily, patients with severe decompensation may be hypotensive due to decreased peripheral tissue perfusion.<xref ref-type="bibr" rid="article-164817.r59">[59]</xref>&#x000a0;Cardiopulmonary auscultation may reveal rales or an S3 or loud P2 heart sound.<xref ref-type="bibr" rid="article-164817.r58">[58]</xref>&#x000a0;Pitting edema of the lower extremities may be observed; presacral pitting edema may be noted in nonambulatory patients. Hepatomegaly may be observed, which may be tender in acute decompensation. A hepatojugular reflex and ascites&#x000a0;demonstrable by a fluid wave or changes in abdominal percussion&#x000a0;are evidence of significant peripheral congestion.</p>
      </sec>
      <sec id="article-164817.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Exertional dyspnea is a common clinical complaint. The clinical signs and symptoms of heart failure are reported and&#x000a0;observed in many disease processes. Additionally, the overt manifestations of HFpEF are common to all subtypes of heart failure, making diagnosing HFpEF challenging.<xref ref-type="bibr" rid="article-164817.r60">[60]</xref> It is reasonable to suspect HFpEF as a possible diagnosis in any patient with exertional dyspnea and one of the following clinical parameters not otherwise explained by an alternative diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age 60 or older</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation<xref ref-type="bibr" rid="article-164817.r61">[61]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Overweight/obesity&#x000a0;<xref ref-type="bibr" rid="article-164817.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Diagnostic algorithms such as the HFA-PEFF (Heart Failure Association. <bold>P</bold>retest Assessment, <bold>E</bold>chocardiography and natriuretic peptide, <bold>F</bold>unctional testing, <bold>F</bold>inal etiology) and H<sub>2</sub>FPEF (<bold>H</bold>eavy, <bold>2</bold> or more hypertensive drugs, atrial <bold>F</bold>ibrillation, <bold>P</bold>ulmonary hypertension, <bold>E</bold>lder&#x000a0;older than&#x000a0;60, elevated <bold>F</bold>illing pressures) have been developed and evaluated to identify HFpEF noninvasively. Additional testing, such as echocardiography and measurement of natriuretic peptides, is required to apply these algorithms and confirm a diagnosis of HFpEF.<xref ref-type="bibr" rid="article-164817.r60">[60]</xref></p>
        <p>An evidence-based diagnostic approach to patients with suspected HFpEF is outlined in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;For patients presenting with a sign or symptom of HFpEF, additional testing is recommended to establish the diagnosis and, if possible, the specific etiology; the presence of underlying comorbidities should also be determined and documented (see <bold>Image.</bold> Flowsheet).</p>
        <p>
<bold>Initial&#x000a0;Evaluation: Laboratory Testing</bold>
</p>
        <p><bold>Complete blood count:</bold>&#x000a0;Anemia is an established risk factor for heart failure and negatively affects clinical outcomes; the negative impact is inversely proportional to the hemoglobin level.<xref ref-type="bibr" rid="article-164817.r62">[62]</xref></p>
        <p><bold>Serum electrolytes, including sodium, potassium, calcium, and magnesium:</bold>&#x000a0;Hyponatremia and hypochloremia are strong adverse prognostic indicators in patients with heart failure.<xref ref-type="bibr" rid="article-164817.r63">[63]</xref></p>
        <p><bold>Serum creatinine and blood urea nitrogen:</bold>&#x000a0;Chronic kidney disease is an established risk factor for heart failure and negatively affects clinical outcomes; the negative impact is inversely proportional to the estimated glomerular filtration rate (eGFR).<xref ref-type="bibr" rid="article-164817.r62">[62]</xref></p>
        <p><bold>Serum glucose:</bold>&#x000a0;Diabetes is a common comorbidity and an underlying risk factor for the development of HFpEF.<xref ref-type="bibr" rid="article-164817.r18">[18]</xref></p>
        <p><bold>Fasting lipid profile:</bold>&#x000a0;Multiple recent studies have suggested that dysregulation of lipid metabolism may contribute to the pathophysiology of HFpEF, HFpEF may alter lipid metabolism, and hypertriglyceridemia may increase the risk of mortality and rehospitalization in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r61">[61]</xref><xref ref-type="bibr" rid="article-164817.r64">[64]</xref><xref ref-type="bibr" rid="article-164817.r65">[65]</xref></p>
        <p><bold>Liver function tests:</bold>&#x000a0;Metabolic dysfunction-associated steatotic liver disease (MASLD; previously nonalcoholic fatty liver disease or NAFLD) has been closely demonstrated to increase the development and progression of HFpEF.<xref ref-type="bibr" rid="article-164817.r66">[66]</xref>&#x000a0;It has been proposed that several MASLD-associated HFpEF phenotypes are commonly encountered in clinical practice.<xref ref-type="bibr" rid="article-164817.r66">[66]</xref></p>
        <p><bold>Iron studies, including serum iron, ferritin, and transferrin saturation:</bold>&#x000a0;Intravenous iron therapy in symptomatic, iron-deficient patients with heart failure has been shown to improve functional status and quality of life and reduce hospitalizations for worsening heart failure.<xref ref-type="bibr" rid="article-164817.r67">[67]</xref></p>
        <p><bold>Thyroid-stimulating hormone:</bold>&#x000a0;Hypothyroid and hyperthyroid states are underlying risk factors for the development of heart failure, and low triiodothyronine syndrome is commonly encountered in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r68">[68]</xref></p>
        <p><bold>B-type natriuretic peptide (BNP) or N-terminal prohormone of&#x000a0;B-type natriuretic peptide (NT-proBNP):</bold>&#x000a0;Measurement of either natriuretic peptide is helpful to exclude or support a diagnosis of heart failure.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;No scientific evidence exists to advocate using one test over another; using their respective values and endpoints interchangeably is inappropriate.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;However, measuring natriuretic peptides in the outpatient setting in patients with dyspnea and an equivocal physical examination provides minimal diagnostic value.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;Many cardiac and noncardiac conditions can cause elevation in natriuretic peptide levels, including advancing age, atrial fibrillation, and chronic kidney disease.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Initial&#x000a0;Evaluation: Noninvasive Testing and Cardiac Imaging</bold>
</p>
        <p><bold>12-lead electrocardiogram (ECG):</bold>&#x000a0;Electrocardiography is routinely performed to evaluate patients with suspected heart failure to obtain information regarding rate, rhythm, and ventricular conduction.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;</p>
        <p><bold>Chest radiography:</bold>&#x000a0;A chest x-ray is indicated in the initial evaluation of patients with suspected HFpEF.<xref ref-type="bibr" rid="article-164817.r69">[69]</xref>&#x000a0;Chest radiography permits the assessment of the cardiac silhouette and heart size, pulmonary airspaces, vascular congestion, and other thoracic disease processes that may contribute to exertional dyspnea.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;</p>
        <p><bold>Transthoracic Echocardiography (TTE):</bold>&#x000a0;Echocardiography is perhaps the most helpful tool in diagnosing HFpEF and is strongly recommended.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;The need to categorize heart failure is considered an indication to perform TTE.<xref ref-type="bibr" rid="article-164817.r70">[70]</xref>&#x000a0;Determination of&#x000a0;LVEF is the critical step in classifying heart failure and guides evidence-based therapeutic interventions.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;If TTE is inadequate, other cardiac imaging studies such as cardiac magnetic resonance, cardiac computed tomography, or radionuclide imaging can be considered.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;However, TTE provides a wealth of information in a noninvasive manner, including the size, function, motion, and geometry of all cardiac chambers and valves, estimates of LVFPs, and estimates of atrial, systolic pulmonary artery, and central venous pressures.</p>
      </sec>
      <sec id="article-164817.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Therapeutic Interventions in Heart Failure with Preserved Ejection Fraction</bold>
</p>
        <p>The goals of therapy for HFpEF are to reduce symptoms, improve quality of life, prevent disease progression, reduce hospitalizations, and effectively manage underlying comorbidities. To this end, lifestyle and behavioral modifications are a cornerstone of therapeutic intervention.</p>
        <p>
<bold>Lifestyle interventions</bold>
</p>
        <p>Several studies have demonstrated that exercise training improves cardiorespiratory fitness and quality of life in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r71">[71]</xref>&#x000a0;Exercise training, exercise-based cardiac rehabilitation, and weight loss improve functional status, exercise performance, rates of heart failure-specific hospitalization, and quality of life in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r72">[72]</xref>&#x000a0;Caloric restriction and exercise training may have positive additive effects in patients with HFpEF,&#x000a0;especially&#x000a0;if they are older with concomitant obesity.<xref ref-type="bibr" rid="article-164817.r73">[73]</xref>&#x000a0;In addition to caloric restriction, at least 1 study has demonstrated that sodium restriction as part of the Dietary Approaches to Stop Hypertension (DASH) diet improves ventricular diastolic function and arterial elastance in patients with HFpEF and hypertension.<xref ref-type="bibr" rid="article-164817.r74">[74]</xref></p>
        <p>
<bold>Antihypertensive therapies</bold>
</p>
        <p>Diuretics, angiotensin receptor&#x02013;neprilysin inhibitors (ARNIs), angiotensin receptor blockers (ARBs), and mineralocorticoid antagonists (MRAs) are the preferred pharmacologic interventions if blood pressure is uncontrolled in a patient with HFpEF. The currently recommended blood pressure goal is below 130/80 mm Hg.<xref ref-type="bibr" rid="article-164817.r12">[12]</xref>&#x000a0;The nonrandomized Optimize-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry demonstrated improved&#x000a0;30-day mortality and decreased hospitalization for heart failure with diuretic use compared to no diuretic therapy after hospital discharge for heart failure.<xref ref-type="bibr" rid="article-164817.r75">[75]</xref>&#x000a0;Bumetanide and torsemide have better bioavailability than furosemide. Some patients may require a combination of diuretic classes, such as thiazide or thiazide-like diuretics. Diuretic resistance is a common problem and may be due to excessive dietary sodium consumption, using medications that negatively affect diuretic action, such as nonsteroidal anti-inflammatory drugs, or underlying chronic kidney disease.</p>
        <p>A meta-analysis of 11 trials of 14,262 patients in sinus rhythm, including 244 patients with HFpEF, demonstrated that beta blockers reduce mortality and have beneficial effects.<xref ref-type="bibr" rid="article-164817.r76">[76]</xref>&#x000a0;Patients with HFpEF and concomitant coronary artery disease also benefit from beta-blocker administration. The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial was a randomized, double-blind trial of 3445 patients with symptomatic heart failure and an LVEF of greater than&#x000a0;45% that demonstrated some reduction in hospitalization rates for heart failure.<xref ref-type="bibr" rid="article-164817.r77">[77]</xref>&#x000a0;This was particularly true for patients with an LVEF of less than 55% to 60% and those with elevated BNP.<xref ref-type="bibr" rid="article-164817.r78">[78]</xref></p>
        <p>A prespecified subgroup analysis of patients in the Prospective Comparison of ARNI with ARB Global Outcomes in HFpEF (PARAGON-HF) demonstrated that sacubitril-valsartan, as compared with valsartan, has a tendency to lower the risk of heart failure-related hospitalizations overall, but more so in women with HFpEF than men; the average LVEF in study participants was 57%.<xref ref-type="bibr" rid="article-164817.r79">[79]</xref>&#x000a0;</p>
        <p>
<bold>Sodium-glucose cotransporter 2 inhibitor therapy&#x000a0;</bold>
</p>
        <p>The effects of sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy on cardiovascular mortality and hospitalization in patients with HFpEF has been demonstrated in the&#x000a0;Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) and Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-PRESERVED) trials.<xref ref-type="bibr" rid="article-164817.r80">[80]</xref>&#x000a0;The DELIVER trial demonstrated that dapagliflozin decreased the risk of worsening heart failure or cardiovascular death among patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r81">[81]</xref>&#x000a0;The EMPEROR-PRESERVED trial demonstrated significant reductions in cardiovascular mortality, heart failure-related hospitalizations, decline in kidney function, and improved quality of life in patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r82">[82]</xref>&#x000a0;The effects of SGLTi therapy are consistent for patients with HFpEF across all age groups, and increasing age has not been associated with an increase in adverse events.<xref ref-type="bibr" rid="article-164817.r16">[16]</xref><xref ref-type="bibr" rid="article-164817.r83">[83]</xref>&#x000a0;SGLT2i therapy should be considered in all patients with&#x000a0;HFpEF, with or without underlying type 2 diabetes, as early as index hospitalization after initial medical stabilization.<xref ref-type="bibr" rid="article-164817.r81">[81]</xref></p>
        <p>In patients with HFpEF, obesity, and underlying type 2 diabetes, glucagon-like peptide (GLP-1) analogs or glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists are beneficial if dual therapy is required.<xref ref-type="bibr" rid="article-164817.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>Rate control in atrial fibrillation</bold>
</p>
        <p>Beta blockers and nondihydropyridine calcium channel blockers are the preferred therapies for rate control in patients with atrial fibrillation and HFpEF. Digoxin may be considered in hypotensive patients. Atrial fibrillation in patients with HFpEF and hypertrophic cardiomyopathy, cardiac amyloidosis, rheumatic mitral valve stenosis, or a mechanical mitral valve requires anticoagulation regardless of CHA<sub>2</sub>DS<sub>2</sub>-VASc score. The 2023 ACC/AHA Guideline for the Diagnosis and Management of Atrial Fibrillation recommends catheter ablation as a first-line therapy to improve symptoms of paroxysmal atrial fibrillation in younger patients with fewer comorbidities.<xref ref-type="bibr" rid="article-164817.r84">[84]</xref></p>
        <p>
<bold>Additional therapies</bold>
</p>
        <p>In patients with HFpEF and suspected sleep apnea, consultation with sleep medicine for possible polysomnography is recommended. Fatigue is a common symptom of heart failure, and daytime sleepiness is a common symptom of sleep apnea; obesity is a risk factor for both disease processes.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref></p>
        <p>Using CardioMEMS, a pulmonary artery pressure hemodynamic monitoring system, improves quality of life and decreases hospitalizations in patients with HFpEF and frequent hospitalizations.<xref ref-type="bibr" rid="article-164817.r85">[85]</xref>&#x000a0;Additionally, CardioMEMS utilization has been shown to improve underlying metabolic comorbidities in tandem with improving pulmonary artery pressures.<xref ref-type="bibr" rid="article-164817.r85">[85]</xref></p>
        <p>Coronary angiogram and revascularization should be considered if ischemia is driving symptoms of HFpEF.<xref ref-type="bibr" rid="article-164817.r86">[86]</xref>&#x000a0;</p>
        <p>The 2022 ACC/AHA Guideline for the Management of Heart Failure recommends that all patients with a diagnosis of heart failure receive palliative and supportive care.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref> In the context of patients with HFpEF, palliative care is defined as "patient- and family-centered care that optimizes health-related quality of life by anticipating, preventing, and treating suffering."<xref ref-type="bibr" rid="article-164817.r1">[1]</xref>&#x000a0;Primary palliative care should begin early in the course of illness, and the interdisciplinary team can address many primary needs.<xref ref-type="bibr" rid="article-164817.r87">[87]</xref>&#x000a0;Components of primary palliative care include high-quality communication, anticipatory guidance, advance care planning, home and case management assistance, care coordination, and addressing barriers to care such as food insecurity and transportation needs.<xref ref-type="bibr" rid="article-164817.r1">[1]</xref><xref ref-type="bibr" rid="article-164817.r87">[87]</xref><xref ref-type="bibr" rid="article-164817.r88">[88]</xref></p>
        <p>
<bold>Acute Decompensation of Heart Failure with Preserved Ejection Fraction</bold>
</p>
        <p>Multidisciplinary shock team assessment and intervention can improve 30-day all-cause mortality and reduce in-hospital mortality in patients with clinical and hemodynamics-proven cardiogenic shock of any etiology.<xref ref-type="bibr" rid="article-164817.r89">[89]</xref>&#x000a0;Intravenous vasopressor support can temporarily improve hemodynamics in patients with cardiogenic shock and improve end-organ perfusion; norepinephrine is preferred except in patients with tachyarrhythmias who benefit from phenylephrine. Vasopressor support allows time for diuresis and correction of precipitating factors like arrhythmia and ischemia.</p>
        <p>Appropriate ventilatory support and diuresis are the cornerstones of therapy for patients with acutely decompensated HFpEF. In most cases, loop&#x000a0;diuretics are preferred to thiazide diuretics; there is no scientific evidence to support one loop diuretic over another in acutely decompensated patients with HFpEF. The Diuretic Optimization Strategies Evaluation (DOSE) trial revealed no clinically significant differences in symptomatic improvement between bolus&#x000a0;or continuous intravenous loop diuretics.<xref ref-type="bibr" rid="article-164817.r90">[90]</xref>&#x000a0;Some patients may require a combination of diuretic classes, such as thiazide, thiazide-like, or acetazolamide. Adding metolazone increases the risk of hypokalemia, hyponatremia, worsening renal function, and mortality compared to loop diuretics alone.<xref ref-type="bibr" rid="article-164817.r91">[91]</xref>&#x000a0;Contrarily, the Acetazolamide in Decompensated Heart Failure with Volume OveRload (ADVOR) trial demonstrated that adding acetazolamide to loop diuretics increases the incidence of successful decongestion in patients with acute heart failure within three days compared to placebo.<xref ref-type="bibr" rid="article-164817.r92">[92]</xref></p>
        <p>Following the initial stabilization of hemodynamics and ventilation, assessing and managing ischemia, arrhythmia, and other precipitating factors and comorbidities is paramount. Urgent revascularization is preferred&#x000a0;in the setting of acute coronary syndrome. Intravenous or topical nitroglycerin is preferred in patients with hypertensive urgency or emergency and pulmonary edema; nitroglycerin decreases preload in patients with pulmonary edema.</p>
        <p>Short-term renal replacement therapy or ultrafiltration should be considered in symptomatic hypervolemic patients with poor renal function and minimal urine output, irrespective of supportive therapy and stable hemodynamics. Patients with poor baseline renal function or end-stage renal disease are at a significantly increased risk for requiring renal replacement therapy.</p>
        <p>There is no substantial evidence supporting the early initiation of angiotensin-converting enzyme (ACE) inhibitors, ARBs, ARNIs, MRAs, SGLT2i therapy, or beta blockers to prevent major adverse cardiac events in unstable patients with acutely decompensated HFpEF. Thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin or saxagliptin are contraindicated in acutely decompensated HFpEF.</p>
      </sec>
      <sec id="article-164817.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of exertional dyspnea with or without generalized fatigue is&#x000a0;extensive and includes cardiac and noncardiac etiologies. Additionally, because the clinical syndrome of heart failure is the common endpoint for many disease processes, the overarching differential diagnosis for heart failure is similarly broad. However, in patients with exertional dyspnea and an underlying risk factor for HFpEF or comorbidity strongly associated with the development of HFpEF, the following diagnoses should be considered:<xref ref-type="bibr" rid="article-164817.r7">[7]</xref><xref ref-type="bibr" rid="article-164817.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Valvular disease, particularly left-sided valvular disease</p>
          </list-item>
          <list-item>
            <p>Infiltrative cardiac diseases such as amyloidosis, hemochromatosis, and sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Hypertrophic cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Constrictive pericarditis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-164817.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with HFpEF have increased rates of morbidity and mortality compared with patients without heart failure. However, recent studies suggest that morbidity rates are similar for patients with HFpEF and HFrEF.<xref ref-type="bibr" rid="article-164817.r27">[27]</xref><xref ref-type="bibr" rid="article-164817.r93">[93]</xref>&#x000a0;The presence and severity of common comorbidities such as hypertension, atrial fibrillation, diabetes, and chronic kidney disease significantly influence the prognosis of patients with HFpEF.<xref ref-type="bibr" rid="article-164817.r27">[27]</xref><xref ref-type="bibr" rid="article-164817.r94">[94]</xref><xref ref-type="bibr" rid="article-164817.r27">[27]</xref>&#x000a0;Biomarkers like BNP, NT-pro BNP, and high-sensitivity troponin are associated with prognosis in HFpEF; elevated biomarker levels may indicate increased cardiovascular risk.</p>
        <p>Independent predictors of mortality in patients with HFpEF confer a poor prognosis.<xref ref-type="bibr" rid="article-164817.r10">[10]</xref><xref ref-type="bibr" rid="article-164817.r52">[52]</xref><xref ref-type="bibr" rid="article-164817.r36">[36]</xref><xref ref-type="bibr" rid="article-164817.r53">[53]</xref><xref ref-type="bibr" rid="article-164817.r94">[94]</xref>&#x000a0;These predictors include but are not limited to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Older age</p>
          </list-item>
          <list-item>
            <p>Male sex</p>
          </list-item>
          <list-item>
            <p>NYHA class C or D</p>
          </list-item>
          <list-item>
            <p>Lower LVEF and the degree of diastolic dysfunction</p>
          </list-item>
          <list-item>
            <p>Extent of coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Peripheral artery disease</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Functional renal impairment</p>
          </list-item>
          <list-item>
            <p>Pulmonary hypertension</p>
          </list-item>
          <list-item>
            <p>Right ventricular dysfunction</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation</p>
          </list-item>
          <list-item>
            <p>Increased red cell distribution width.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-164817.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications stemming from HFpEF are multifaceted, reflecting the intricate interplay of diverse risk factors, complex pathophysiological processes, and the heterogeneous nature of this clinical syndrome. Left atrial dysfunction, atrial fibrillation, and pulmonary hypertension often develop, placing an increased workload on the right ventricle and increasing the risk of biventricular failure.&#x000a0;</p>
        <p>Beyond cardiovascular implications, HFpEF introduces complications associated with comorbidities such as obesity, diabetes, and chronic kidney disease. Impaired exercise tolerance and functional decline are common, as diminished physiologic reserve manifests in more severe dyspnea and fatigue, impacting daily activities.</p>
        <p>Diagnostic challenges and overlapping symptoms make timely identification complex, potentially delaying appropriate interventions. Therapeutic challenges arise from the varied responses to interventions among HFpEF patients, necessitating a personalized, multidisciplinary approach to manage these complications effectively. Ongoing research endeavors aim to deepen our understanding and refine strategies for addressing the intricate complications associated with HFpEF, ultimately enhancing patient outcomes and quality of life.</p>
      </sec>
      <sec id="article-164817.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients with HFpEF typically present to a primary care provider with complaints of exertional dyspnea, activity intolerance, and fatigue. However, the diagnosis of HFpEF may require the expertise of a cardiologist. Once a diagnosis of HFpEF is made, patients require consultation with the cardiac rehabilitation team, cardiac nursing, and a cardiac dietitian. Underlying comorbidities may necessitate consultation with interventional cardiology, electrophysiology, pulmonology-sleep medicine, endocrinology, or a heart failure specialist. While the primary care team can meet most primary palliative care needs, consultation with social workers, case management, or palliative care specialists may become necessary to identify barriers to adequate care and provide patient- and family-specific support. Evidence supports improved quality of life and decreased hospitalizations in patients with heart failure who receive care at a high-volume heart failure center.<xref ref-type="bibr" rid="article-164817.r95">[95]</xref></p>
      </sec>
      <sec id="article-164817.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>All patients with HFpEF should receive counseling and education that emphasizes compliance with dietary and medical therapies; dietary and medical noncompliance are the most common causes of hospital readmission in patients with heart failure.<xref ref-type="bibr" rid="article-164817.r96">[96]</xref>&#x000a0;Additionally, improvement in healthcare literacy is associated with a decreased need for emergency care due to heart failure exacerbations.<xref ref-type="bibr" rid="article-164817.r96">[96]</xref>&#x000a0;Although single-session educational interventions offer the same benefits as multisession interventions for most patients with heart failure, patients with lower levels of healthcare literacy may benefit from multisession interventions.<xref ref-type="bibr" rid="article-164817.r97">[97]</xref></p>
        <p>Free, printable patient education handout materials are available here:</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/Search/3,82055">What is Heart Failure?</ext-link>&#x000a0;A discussion of HFrEF, HFmrEF, and HFpEF explaining LVEF and the signs and symptoms of heart failure.&#x000a0;</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/3,86175">Coping With Heart Failure</ext-link>.&#x000a0;A discussion of patient-led lifestyle behaviors to improve overall well-being and strategies to garner assistance.&#x000a0;</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/3,82088">Heart Failure: How to be Active</ext-link>.&#x000a0;A discussion of ways to safely improve physical activity in patients with heart failure.&#x000a0;</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/3,86179">Heart Failure: Assessing Your Heart</ext-link>. A generalized discussion of diagnostic testing and therapeutic interventions for heart failure.</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/3,86177">Heart Failure: Making Changes to Your Diet</ext-link>. A discussion of the adverse effects of fluid overload and excess sodium, including daily sodium goals, how to read food labels, and when to contact a healthcare practitioner.&#x000a0;&#x000a0;</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/3,82087">Heart Failure: Tracking Your Weight</ext-link>.&#x000a0;A discussion of the importance of regular weight tracking, including&#x000a0;instructions for properly using a weight chart.</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/3,82086">Heart Failure: Warning Signs of a Flare-Up</ext-link>.&#x000a0;A discussion of the signs and symptoms that may indicate the acute decompensation of heart failure and when to contact a healthcare practitioner.&#x000a0;</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.veteranshealthlibrary.va.gov/RelatedItems/142,82026_VA">Taking Medicine to Control Heart Failure</ext-link>. A discussion of strategies to include compliance with heart failure medications, including diuretics, SGLT2 inhibitors, aldosterone blockers, beta blockers, angiotensin receptor neprilysin inhibitors, angiotensin receptor blockers, ACE inhibitors, hydralazine and nitrates, digoxin, sinus node I-f channel blockers, and statins.</p>
      </sec>
      <sec id="article-164817.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of HFpEF requires a collaborative effort among healthcare professionals, including physicians, advanced practice providers, nurses, pharmacists, and others, to enhance patient-centered care, improve outcomes, ensure patient safety, and optimize team performance. Given that heart failure represents a common endpoint for various disease processes, including ischemic heart disease secondary to coronary artery disease, addressing the underlying etiologies and risk factors is crucial.</p>
        <p>HFpEF is a heterogeneous clinical syndrome with predisposing conditions that involve increasing age, female sex, atrial fibrillation, pulmonary hypertension, obesity, and diabetes. Additionally, HFpEF may result from multiple risk factors, including sleep apnea, chronic obstructive pulmonary disease, iron deficiency, coronary artery disease, atrial fibrillation, and dysrhythmias. The complexity of HFpEF necessitates a multidisciplinary approach, and the exact pathogenic role of each risk factor remains incompletely understood.</p>
        <p>Diagnosing HFpEF is challenging due to common clinical manifestations and the overlap with other heart failure subtypes. Diagnostic algorithms, such as HFA-PEFF and H2FPEF, along with additional testing like echocardiography and natriuretic peptide measurement, are employed to confirm the diagnosis. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure provides an evidence-based diagnostic approach.</p>
        <p>Therapeutic interventions for HFpEF focus on reducing symptoms, improving quality of life, preventing disease progression, and managing comorbidities. Lifestyle modifications, including exercise training, weight loss, and sodium restriction, are cornerstones of treatment. Antihypertensive therapies, including diuretics, ARNIs, ARBs, and MRAs, are recommended, with a blood pressure goal lower than 130/80 mm Hg. Beta-blockers, sacubitril-valsartan, and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are shown to have beneficial effects. Consultation with sleep medicine is recommended in patients with HFpEF and suspected sleep apnea.</p>
        <p>For acute decompensation of HFpEF, a multidisciplinary shock team assessment involving intravenous vasopressors, appropriate ventilation support, and diuresis is crucial. Renal replacement therapy may be considered in patients with poor renal function. However, the early initiation of certain medications, such as ACE inhibitors, ARBs, ARNIs, MRAs, SGLT2 inhibitors, and beta-blockers, lacks substantial evidence for preventing major adverse cardiac events in unstable acute decompensated HFpEF.</p>
        <p>The 2022 ACC/AHA Guideline emphasizes palliative and supportive care for all patients with heart failure, including those with HFpEF. Primary palliative care should begin early and address high-quality communication, advance care planning, home and case management assistance, and other needs. The complexity of HFpEF necessitates ongoing research and a comprehensive, team-based approach to optimize patient outcomes.</p>
      </sec>
      <sec id="article-164817.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=164817&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=164817">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/heart-failure-with-preserved-ejection-fraction-hfpef-heart-failure/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=164817">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/164817/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=164817">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-164817.s16">
        <fig id="article-164817.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pathophysiology of Heart Failure Contributed by MS Golla, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image__.__Pathophysiology__of__heart__failure" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-164817.s17">
        <fig id="article-164817.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Assessment of Patients with Suspected Heart Failure Flowsheet Contributed by MS Golla, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Heart__failure__assessment" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-164817.s18">
        <title>References</title>
        <ref id="article-164817.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Heart Failure With Preserved Ejection Fraction In Perspective.</article-title>
            <source>Circ Res</source>
            <year>2019</year>
            <month>May</month>
            <day>24</day>
            <volume>124</volume>
            <issue>11</issue>
            <fpage>1598</fpage>
            <page-range>1598-1617</page-range>
            <pub-id pub-id-type="pmid">31120821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and aetiology of heart failure.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>368</fpage>
            <page-range>368-78</page-range>
            <pub-id pub-id-type="pmid">26935038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ammar</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kors</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rodeheffer</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community.</article-title>
            <source>Circulation</source>
            <year>2007</year>
            <month>Mar</month>
            <day>27</day>
            <volume>115</volume>
            <issue>12</issue>
            <fpage>1563</fpage>
            <page-range>1563-70</page-range>
            <pub-id pub-id-type="pmid">17353436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Fleg</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function.</article-title>
            <source>Am Heart J</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>151</volume>
            <issue>2</issue>
            <fpage>444</fpage>
            <page-range>444-50</page-range>
            <pub-id pub-id-type="pmid">16442912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>YNV</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Handoko</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>van de Bovenkamp</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tedford</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Keck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Obokata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verbrugge</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea.</article-title>
            <source>JAMA Cardiol</source>
            <year>2022</year>
            <month>Sep</month>
            <day>01</day>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>891</fpage>
            <page-range>891-899</page-range>
            <pub-id pub-id-type="pmid">35830183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gazewood</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Heart Failure with Preserved Ejection Fraction: Diagnosis and Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>96</volume>
            <issue>9</issue>
            <fpage>582</fpage>
            <page-range>582-588</page-range>
            <pub-id pub-id-type="pmid">29094875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rame</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ramilo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blewett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dries</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction.</article-title>
            <source>Am J Cardiol</source>
            <year>2004</year>
            <month>Jan</month>
            <day>15</day>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>234</fpage>
            <page-range>234-7</page-range>
            <pub-id pub-id-type="pmid">14715358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tromp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jhund</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Komajda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKelvie</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
            </person-group>
            <article-title>Age-Related Characteristics and Outcomes of Patients With Heart&#x000a0;Failure With Preserved Ejection Fraction.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>06</day>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>601</fpage>
            <page-range>601-612</page-range>
            <pub-id pub-id-type="pmid">31370950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melenovsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Zakeri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.</article-title>
            <source>Circ Heart Fail</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-303</page-range>
            <pub-id pub-id-type="pmid">25593126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Baicu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Bonnema</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Diastolic heart failure: definitions and terminology.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-13</page-range>
            <pub-id pub-id-type="pmid">16003645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Panjrath</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Amancherla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2023</year>
            <month>May</month>
            <day>09</day>
            <volume>81</volume>
            <issue>18</issue>
            <fpage>1835</fpage>
            <page-range>1835-1878</page-range>
            <pub-id pub-id-type="pmid">37137593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ogden</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bazzano</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Vupputuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.</article-title>
            <source>Arch Intern Med</source>
            <year>2001</year>
            <month>Apr</month>
            <day>09</day>
            <volume>161</volume>
            <issue>7</issue>
            <fpage>996</fpage>
            <page-range>996-1002</page-range>
            <pub-id pub-id-type="pmid">11295963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amiya</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Social and environmental risks as contributors to the clinical course of heart failure.</article-title>
            <source>Heart Fail Rev</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>1001</fpage>
            <page-range>1001-1016</page-range>
            <pub-id pub-id-type="pmid">33945055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White-Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Driscoll</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Durant</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Graven</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kitko</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Newlin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shirey</surname>
                <given-names>M</given-names>
              </name>
              <collab>American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Epidemiology and Prevention</collab>
            </person-group>
            <article-title>Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Jun</month>
            <day>02</day>
            <volume>141</volume>
            <issue>22</issue>
            <fpage>e841</fpage>
            <page-range>e841-e863</page-range>
            <pub-id pub-id-type="pmid">32349541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Usman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Cicoira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cosentino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jankowska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mullens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gonzalez-Juanatey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rakisheva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savarese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Teerlink</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tsch&#x000f6;pe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Volterrani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Haehling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zieroth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bayes-Genis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chioncel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Andreotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agabiti-Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merino</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
            </person-group>
            <article-title>Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>936</fpage>
            <page-range>936-955</page-range>
            <pub-id pub-id-type="pmid">37461163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savarese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Becher</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
            </person-group>
            <article-title>Global burden of heart failure: a comprehensive and updated review of epidemiology.</article-title>
            <source>Cardiovasc Res</source>
            <year>2023</year>
            <month>Jan</month>
            <day>18</day>
            <volume>118</volume>
            <issue>17</issue>
            <fpage>3272</fpage>
            <page-range>3272-3287</page-range>
            <pub-id pub-id-type="pmid">35150240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Patorno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barberio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model.</article-title>
            <source>Clin Epidemiol</source>
            <year>2020</year>
            <volume>12</volume>
            <fpage>607</fpage>
            <page-range>607-616</page-range>
            <pub-id pub-id-type="pmid">32606986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>YNV</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Obokata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abou-Ezzedine</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Fudim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McNulty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LeWinter</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>94</volume>
            <issue>7</issue>
            <fpage>1199</fpage>
            <page-range>1199-1209</page-range>
            <pub-id pub-id-type="pmid">31272568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eaton</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Pettinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossouw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Foraker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quddus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wampler</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Hank Wu</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corbie-Smith</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosamond</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Breathett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal Women.</article-title>
            <source>Circ Heart Fail</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">27682440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>CWL</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical Low-Gradient Aortic Stenosis: The HFpEF of Aortic Stenosis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>May</month>
            <day>24</day>
            <volume>67</volume>
            <issue>20</issue>
            <fpage>2447</fpage>
            <page-range>2447-2448</page-range>
            <pub-id pub-id-type="pmid">27199070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lopatin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>De Marco</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <collab>ADHERE Scientific Advisory Committee and Investigators</collab>
            </person-group>
            <article-title>Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2006</year>
            <month>Jan</month>
            <day>03</day>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-84</page-range>
            <pub-id pub-id-type="pmid">16386668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Bosak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Breathett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hsich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koelling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Khush</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stehlik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Teerlink</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vaduganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
              <collab>Writing Committee Members</collab>
            </person-group>
            <article-title>Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America.</article-title>
            <source>J Card Fail</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1412</fpage>
            <page-range>1412-1451</page-range>
            <pub-id pub-id-type="pmid">37797885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasan</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Enserro</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Beiser</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Xanthakis</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Lifetime Risk of Heart&#x000a0;Failure Among Participants in the Framingham Study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>25</day>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-263</page-range>
            <pub-id pub-id-type="pmid">35057911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ayers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>LaMonte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Kuller</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Greenland</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Gottdiener</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Apr</month>
            <day>24</day>
            <volume>137</volume>
            <issue>17</issue>
            <fpage>1814</fpage>
            <page-range>1814-1823</page-range>
            <pub-id pub-id-type="pmid">29352072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Wruck</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Shahar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Loehr</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rosamond</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Jul</month>
            <day>03</day>
            <volume>138</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-24</page-range>
            <pub-id pub-id-type="pmid">29519849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsao</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lyass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Enserro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kizer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gottdiener</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Psaty</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Vasan</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Temporal Trends in the Incidence of&#x000a0;and&#x000a0;Mortality Associated With Heart&#x000a0;Failure With Preserved and Reduced Ejection Fraction.</article-title>
            <source>JACC Heart Fail</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>678</fpage>
            <page-range>678-685</page-range>
            <pub-id pub-id-type="pmid">30007560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haruta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katoh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hattori</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Haruki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kogure</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uetsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hagiwara</surname>
                <given-names>N</given-names>
              </name>
              <collab>HIJ-HF II Investigators</collab>
            </person-group>
            <article-title>Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.</article-title>
            <source>ESC Heart Fail</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-486</page-range>
            <pub-id pub-id-type="pmid">30829002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hales</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tofler</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and outcome for heart failure patients with mid-range ejection fraction.</article-title>
            <source>J Cardiovasc Med (Hagerstown)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>297</fpage>
            <page-range>297-303</page-range>
            <pub-id pub-id-type="pmid">29570491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chioncel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lainscak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Crespo-Leiro</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Harjola</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Parissis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piepoli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ambrosio</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1574</fpage>
            <page-range>1574-1585</page-range>
            <pub-id pub-id-type="pmid">28386917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenchaiah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kannel</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Vasan</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Obesity and the risk of heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Aug</month>
            <day>01</day>
            <volume>347</volume>
            <issue>5</issue>
            <fpage>305</fpage>
            <page-range>305-13</page-range>
            <pub-id pub-id-type="pmid">12151467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitzman</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>The HFpEF Obesity Phenotype: The Elephant in the Room.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>12</day>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-3</page-range>
            <pub-id pub-id-type="pmid">27386774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>O'Moore-Sullivan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Beller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marwick</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Alterations of left ventricular myocardial characteristics associated with obesity.</article-title>
            <source>Circulation</source>
            <year>2004</year>
            <month>Nov</month>
            <day>09</day>
            <volume>110</volume>
            <issue>19</issue>
            <fpage>3081</fpage>
            <page-range>3081-7</page-range>
            <pub-id pub-id-type="pmid">15520317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Homma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rundek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Elkind</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Di Tullio</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2011</year>
            <month>Mar</month>
            <day>22</day>
            <volume>57</volume>
            <issue>12</issue>
            <fpage>1368</fpage>
            <page-range>1368-74</page-range>
            <pub-id pub-id-type="pmid">21414533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wohlfahrt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lopez-Jimenez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melenovsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Rodeheffer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Impact of general and central adiposity on ventricular-arterial aging in women and men.</article-title>
            <source>JACC Heart Fail</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>489</fpage>
            <page-range>489-99</page-range>
            <pub-id pub-id-type="pmid">25194285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gorter</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Celutkiene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Crespo-Leiro</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Guazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harjola</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Heymans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lainscak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Piepoli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rutten</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Triposkiadis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wachter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsch&#x000f6;pe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-37</page-range>
            <pub-id pub-id-type="pmid">29044932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obokata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>YNV</given-names>
              </name>
              <name>
                <surname>Pislaru</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Melenovsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Jul</month>
            <day>04</day>
            <volume>136</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-19</page-range>
            <pub-id pub-id-type="pmid">28381470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Melenovsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>DeSimone</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Gaba</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Killu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naksuk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Asirvatham</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous Pericardial Resection: A Novel Potential Treatment for Heart Failure With Preserved Ejection Fraction.</article-title>
            <source>Circ Heart Fail</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e003612</fpage>
            <pub-id pub-id-type="pmid">28396500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>07</day>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>845</fpage>
            <page-range>845-54</page-range>
            <pub-id pub-id-type="pmid">20813282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haykowsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brubaker</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Kitzman</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2011</year>
            <month>Jul</month>
            <day>12</day>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-74</page-range>
            <pub-id pub-id-type="pmid">21737017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haykowsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kouba</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Brubaker</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Eggebeen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kitzman</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction.</article-title>
            <source>Am J Cardiol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>01</day>
            <volume>113</volume>
            <issue>7</issue>
            <fpage>1211</fpage>
            <page-range>1211-6</page-range>
            <pub-id pub-id-type="pmid">24507172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhakal</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Pappagianopoulos</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Baggish</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Houstis</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Eisman</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hough</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.</article-title>
            <source>Circ Heart Fail</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>286</fpage>
            <page-range>286-94</page-range>
            <pub-id pub-id-type="pmid">25344549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molina</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bharadwaj</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Van Horn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lyles</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Eggebeen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haykowsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brubaker</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kitzman</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance.</article-title>
            <source>JACC Heart Fail</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>8</issue>
            <fpage>636</fpage>
            <page-range>636-45</page-range>
            <pub-id pub-id-type="pmid">27179829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>YNV</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Obokata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koepp</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Melenovsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Arterial Stiffening With Exercise in Patients&#x000a0;With Heart Failure and Preserved&#x000a0;Ejection Fraction.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>11</day>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-148</page-range>
            <pub-id pub-id-type="pmid">28683960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houstis</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Eisman</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pappagianopoulos</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Wooster</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O<sub>2</sub> Pathway Analysis.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Jan</month>
            <day>09</day>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <page-range>148-161</page-range>
            <pub-id pub-id-type="pmid">28993402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cikes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Getchevski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Claggett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rizkala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lukashevich</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mullens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <collab>PARAGON-HF Investigators</collab>
            </person-group>
            <article-title>Echocardiographic Features of Patients&#x000a0;With Heart&#x000a0;Failure and Preserved&#x000a0;Left Ventricular Ejection Fraction.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Dec</month>
            <day>10</day>
            <volume>74</volume>
            <issue>23</issue>
            <fpage>2858</fpage>
            <page-range>2858-2873</page-range>
            <pub-id pub-id-type="pmid">31806129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>YNV</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Obokata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melenovsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Hemodynamic Correlates and Diagnostic&#x000a0;Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved&#x000a0;Ejection Fraction.</article-title>
            <source>JACC Heart Fail</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>665</fpage>
            <page-range>665-675</page-range>
            <pub-id pub-id-type="pmid">29803552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borb&#x000e9;ly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bronzwaer</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Edes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stienen</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiomyocyte stiffness in diastolic heart failure.</article-title>
            <source>Circulation</source>
            <year>2005</year>
            <month>Feb</month>
            <day>15</day>
            <volume>111</volume>
            <issue>6</issue>
            <fpage>774</fpage>
            <page-range>774-81</page-range>
            <pub-id pub-id-type="pmid">15699264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Heerebeek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Borb&#x000e9;ly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niessen</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Bronzwaer</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stienen</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Laarman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Myocardial structure and function differ in systolic and diastolic heart failure.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Apr</month>
            <day>25</day>
            <volume>113</volume>
            <issue>16</issue>
            <fpage>1966</fpage>
            <page-range>1966-73</page-range>
            <pub-id pub-id-type="pmid">16618817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Baicu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Gaasch</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>May</month>
            <day>06</day>
            <volume>350</volume>
            <issue>19</issue>
            <fpage>1953</fpage>
            <page-range>1953-9</page-range>
            <pub-id pub-id-type="pmid">15128895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zakeri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Sep</month>
            <day>03</day>
            <volume>128</volume>
            <issue>10</issue>
            <fpage>1085</fpage>
            <page-range>1085-93</page-range>
            <pub-id pub-id-type="pmid">23908348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanderpool</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Saul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nouraie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gladwin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.</article-title>
            <source>JAMA Cardiol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-306</page-range>
            <pub-id pub-id-type="pmid">29541759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammed</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>AbouEzzeddine</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Takahama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Forfia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Right ventricular function in heart failure with preserved ejection fraction: a community-based study.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>23</day>
            <volume>130</volume>
            <issue>25</issue>
            <fpage>2310</fpage>
            <page-range>2310-20</page-range>
            <pub-id pub-id-type="pmid">25391518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulus</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Tsch&#x000f6;pe</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Jul</month>
            <day>23</day>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-71</page-range>
            <pub-id pub-id-type="pmid">23684677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franssen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korkmaz</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>De Keulenaer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Tsch&#x000f6;pe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leite-Moreira</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Musters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Niessen</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hamdani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.</article-title>
            <source>JACC Heart Fail</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>312</fpage>
            <page-range>312-24</page-range>
            <pub-id pub-id-type="pmid">26682792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Baicu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Ikonomidis</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Stroud</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Nietert</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Slater</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Van Buren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Granzier</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>LeWinter</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Apr</month>
            <day>07</day>
            <volume>131</volume>
            <issue>14</issue>
            <fpage>1247</fpage>
            <page-range>1247-59</page-range>
            <pub-id pub-id-type="pmid">25637629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hamdani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Kruger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohtani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogut</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brozovich</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Dec</month>
            <day>20</day>
            <volume>124</volume>
            <issue>25</issue>
            <fpage>2882</fpage>
            <page-range>2882-91</page-range>
            <pub-id pub-id-type="pmid">22144574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Rizkala</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lefkowitz</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anavekar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Arango</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Arenas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Atar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ben-Gal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boytsov</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Comin-Colet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duengen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Echeverr&#x000ed;a Correa</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Flammer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Galinier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goncalvesova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lelonek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linssen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Milicic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Ranjith</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saraiva</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Senni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sibulo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sweitzer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Taurio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vinereanu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vrtovec</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Widimsk&#x000fd;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zweiker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
            </person-group>
            <article-title>Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.</article-title>
            <source>Circ Heart Fail</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>e004962</fpage>
            <pub-id pub-id-type="pmid">29980595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r59">
          <label>59</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Malik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vaqar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chhabra</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Congestive Heart Failure</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">28613623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faxen</surname>
                <given-names>UL</given-names>
              </name>
              <name>
                <surname>Venkateshvaran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Svedlund</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saraste</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beussink-Nelson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lagerstrom Fermer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Hage</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Generalizability of HFA-PEFF and H<sub>2</sub>FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF.</article-title>
            <source>J Card Fail</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>756</fpage>
            <page-range>756-765</page-range>
            <pub-id pub-id-type="pmid">33647474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leggat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bidault</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vidal-Puig</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Lipotoxicity: a driver of heart failure with preserved ejection fraction?</article-title>
            <source>Clin Sci (Lond)</source>
            <year>2021</year>
            <month>Oct</month>
            <day>15</day>
            <volume>135</volume>
            <issue>19</issue>
            <fpage>2265</fpage>
            <page-range>2265-2283</page-range>
            <pub-id pub-id-type="pmid">34643676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerhardt</surname>
                <given-names>LMS</given-names>
              </name>
              <name>
                <surname>Kordsmeyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sehner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>G&#x000fc;der</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>St&#x000f6;rk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edelmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wachter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pankuweit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prettin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ertl</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Angermann</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages.</article-title>
            <source>Clin Res Cardiol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>112</volume>
            <issue>7</issue>
            <fpage>868</fpage>
            <page-range>868-879</page-range>
            <pub-id pub-id-type="pmid">35648270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuthbert</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pellicori</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rigby</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kazmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1426</fpage>
            <page-range>1426-1435</page-range>
            <pub-id pub-id-type="pmid">29943886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Risk Factors for Heart Failure with Preserved Ejection Fraction and Observations on Blood Lipid Metabolism.</article-title>
            <source>Altern Ther Health Med</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>396</fpage>
            <page-range>396-400</page-range>
            <pub-id pub-id-type="pmid">37632969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>YD</given-names>
              </name>
            </person-group>
            <article-title>High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction.</article-title>
            <source>Cardiovasc Diabetol</source>
            <year>2023</year>
            <month>Sep</month>
            <day>29</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>263</fpage>
            <pub-id pub-id-type="pmid">37775762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salah</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soloveva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdelmalek</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Moylan</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Wegermann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Tedford</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Mentz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McGarrah</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Fudim</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Relationship of Nonalcoholic Fatty Liver Disease and Heart&#x000a0;Failure With Preserved Ejection Fraction.</article-title>
            <source>JACC Basic Transl Sci</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>918</fpage>
            <page-range>918-932</page-range>
            <pub-id pub-id-type="pmid">34869957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Comin-Colet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ertl</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Komajda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mareev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tavazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levesque</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roubert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <collab>CONFIRM-HF Investigators</collab>
            </person-group>
            <article-title>Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency&#x02020;.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Mar</month>
            <day>14</day>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>657</fpage>
            <page-range>657-68</page-range>
            <pub-id pub-id-type="pmid">25176939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Luca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crisci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giardino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Amaranto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iacono</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>D'Assante</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giallauria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Anabolic hormones and heart failure with preserved ejection fraction: looking for Ariadne's thread.</article-title>
            <source>Monaldi Arch Chest Dis</source>
            <year>2021</year>
            <month>Aug</month>
            <day>03</day>
            <volume>92</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">34351104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waddell-Smith</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Donoghue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stiles</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Inpatient detection of cardiac-inherited disease: the impact of improving family history taking.</article-title>
            <source>Open Heart</source>
            <year>2016</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>e000329</fpage>
            <pub-id pub-id-type="pmid">26925241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ovchinnikov</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Ageev</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Alekhin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Belenkov</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Vasyuk</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Galyavich</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gilyarevskiy</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lopatin</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Mareev</surname>
                <given-names>VY</given-names>
              </name>
              <name>
                <surname>Mareev</surname>
                <given-names>YV</given-names>
              </name>
              <name>
                <surname>Mitkov</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Potekhina</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Prostakova</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Rybakova</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Saidova</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Khadzegova</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Chernov</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Yuschuk</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Boytsov</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>[The role of diastolic transthoracic stress echocardiography with incremental workload in the evaluation of heart failure with preserved ejection fraction: indications, methodology, interpretation. Expert consensus developed under the auspices of the National Medical Research Center of Cardiology, Society of Experts in Heart Failure (SEHF), and Russian Association of Experts in Ultrasound Diagnosis in Medicine (REUDM)].</article-title>
            <source>Kardiologiia</source>
            <year>2021</year>
            <month>Jan</month>
            <day>19</day>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>48</fpage>
            <page-range>48-63</page-range>
            <pub-id pub-id-type="pmid">33522468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parashar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumbhani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kitzman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials.</article-title>
            <source>Circ Heart Fail</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-40</page-range>
            <pub-id pub-id-type="pmid">25399909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mueller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winzer</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Duvinage</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gevaert</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Edelmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pieske-Kraigher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beckers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bobenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hommel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van de Heyning</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Esefeld</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>von Korn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Christle</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Haykowsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wisl&#x000f8;ff</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Craenenbroeck</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Halle</surname>
                <given-names>M</given-names>
              </name>
              <collab>OptimEx-Clin Study Group</collab>
            </person-group>
            <article-title>Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Feb</month>
            <day>09</day>
            <volume>325</volume>
            <issue>6</issue>
            <fpage>542</fpage>
            <page-range>542-551</page-range>
            <pub-id pub-id-type="pmid">33560320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitzman</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Brubaker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haykowsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hundley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Eggebeen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jan</month>
            <day>05</day>
            <volume>315</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-46</page-range>
            <pub-id pub-id-type="pmid">26746456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hummel</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weder</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kov&#x000e1;cs</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kolias</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.</article-title>
            <source>Circ Heart Fail</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>1165</fpage>
            <page-range>1165-71</page-range>
            <pub-id pub-id-type="pmid">23985432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faselis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arundel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Deedwania</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sheriff</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wopperer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Allman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Loop Diuretic Prescription and 30-Day&#x000a0;Outcomes in Older Patients With&#x000a0;Heart&#x000a0;Failure.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>11</day>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>669</fpage>
            <page-range>669-679</page-range>
            <pub-id pub-id-type="pmid">32762901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cleland</surname>
                <given-names>JGF</given-names>
              </name>
              <name>
                <surname>Bunting</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Flather</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Manzano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>von Lueder</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kjekshus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rigby</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hjalmarson</surname>
                <given-names>&#x000c5;</given-names>
              </name>
              <name>
                <surname>Wikstrand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>D</given-names>
              </name>
              <collab>Beta-blockers in Heart Failure Collaborative Group</collab>
            </person-group>
            <article-title>Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-35</page-range>
            <pub-id pub-id-type="pmid">29040525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Assmann</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Boineau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Claggett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clausell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fleg</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gordeev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Harty</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heitner</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kenwood</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Probstfield</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shaburishvili</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Sweitzer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McKinlay</surname>
                <given-names>SM</given-names>
              </name>
              <collab>TOPCAT Investigators</collab>
            </person-group>
            <article-title>Spironolactone for heart failure with preserved ejection fraction.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Apr</month>
            <day>10</day>
            <volume>370</volume>
            <issue>15</issue>
            <fpage>1383</fpage>
            <page-range>1383-92</page-range>
            <pub-id pub-id-type="pmid">24716680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Claggett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Assmann</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Boineau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Clausell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fleg</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gordeev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Heitner</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Probstfield</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shaburishvili</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Sweitzer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>McKinlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Jan</month>
            <day>06</day>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-42</page-range>
            <pub-id pub-id-type="pmid">25406305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lefkowitz</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rizkala</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Sabarwal</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zile</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cikes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goncalvesova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Katova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kosztin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lelonek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sweitzer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Claggett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jhund</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Feb</month>
            <day>04</day>
            <volume>141</volume>
            <issue>5</issue>
            <fpage>338</fpage>
            <page-range>338-351</page-range>
            <pub-id pub-id-type="pmid">31736337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sevre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wachtell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Devereux</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Aurigemma</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Smiseth</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Julius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The current best drug treatment for hypertensive heart failure with preserved ejection fraction.</article-title>
            <source>Eur J Intern Med</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>120</volume>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">37865559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Claggett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Inzucchi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kosiborod</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Jhund</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Belohlavek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Borleffs</surname>
                <given-names>CJW</given-names>
              </name>
              <name>
                <surname>Comin-Colet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dobreanu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Drozdz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Alcocer-Gamba</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Al Habeeb</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cabrera Honorio</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Katova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitakaze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saraiva</surname>
                <given-names>JFK</given-names>
              </name>
              <name>
                <surname>Tereshchenko</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Thierer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaduganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Wilder&#x000e4;ng</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zaozerska</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bachus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petersson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Langkilde</surname>
                <given-names>AM</given-names>
              </name>
              <collab>DELIVER Trial Committees and Investigators</collab>
            </person-group>
            <article-title>Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Sep</month>
            <day>22</day>
            <volume>387</volume>
            <issue>12</issue>
            <fpage>1089</fpage>
            <page-range>1089-1098</page-range>
            <pub-id pub-id-type="pmid">36027570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bocchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brunner-La Rocca</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chuquiure-Valenzuela</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giannetti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gomez-Mesa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gonzalez-Juanatey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;a</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Senni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spinar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Taddei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsutsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vinereanu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schnaidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schnee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brueckmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <collab>EMPEROR-Preserved Trial Investigators</collab>
            </person-group>
            <article-title>Empagliflozin in Heart Failure with a Preserved Ejection Fraction.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Oct</month>
            <day>14</day>
            <volume>385</volume>
            <issue>16</issue>
            <fpage>1451</fpage>
            <page-range>1451-1461</page-range>
            <pub-id pub-id-type="pmid">34449189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Abdin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahfoud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brueckmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gollop</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <collab>EMPEROR-Preserved Trial Committees and Investigators</collab>
            </person-group>
            <article-title>Empagliflozin Improves Outcomes in&#x000a0;Patients With Heart&#x000a0;Failure and Preserved Ejection Fraction Irrespective of Age.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>05</day>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">35772911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Armbruster</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Chyou</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eckhardt</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Gopinathannair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ibeh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kido</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kusumoto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Linta</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Streur</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Times</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Van Wagoner</surname>
                <given-names>DR</given-names>
              </name>
              <collab>Peer Review Committee Members</collab>
            </person-group>
            <article-title>2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>149</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e156</page-range>
            <pub-id pub-id-type="pmid">38033089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Zyl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nayyar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jermyn</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Improvement in Metabolic Co-Morbidities after Implantation of CardioMEMS in Patients with Heart Failure with Preserved Ejection Fraction Phenotype.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>22</day>
            <volume>10</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">34640323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r86">
          <label>86</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Golla</surname>
                <given-names>MSG</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Percutaneous Transluminal Coronary Arteriography</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30844185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Datla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verberkt</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hoye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>DJA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Multi-disciplinary palliative care is effective in people with symptomatic heart failure: A systematic review and narrative synthesis.</article-title>
            <source>Palliat Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1003</fpage>
            <page-range>1003-1016</page-range>
            <pub-id pub-id-type="pmid">31307276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casarett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Dwyer</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Barg</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Naylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asch</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>How should we design supportive cancer care? The patient's perspective.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <day>10</day>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1296</fpage>
            <page-range>1296-301</page-range>
            <pub-id pub-id-type="pmid">18323553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waagstein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caidahl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bergh</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Hjalmarson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.</article-title>
            <source>Circulation</source>
            <year>1989</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>551</fpage>
            <page-range>551-63</page-range>
            <pub-id pub-id-type="pmid">2548768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Felker</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>LeWinter</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ofili</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Anstrom</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>McNulty</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kfoury</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Givertz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Semigran</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bart</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mascette</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>CM</given-names>
              </name>
              <collab>NHLBI Heart Failure Clinical Research Network</collab>
            </person-group>
            <article-title>Diuretic strategies in patients with acute decompensated heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Mar</month>
            <day>03</day>
            <volume>364</volume>
            <issue>9</issue>
            <fpage>797</fpage>
            <page-range>797-805</page-range>
            <pub-id pub-id-type="pmid">21366472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brisco-Bacik</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ter Maaten</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Houser</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vedage</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Testani</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>7</volume>
            <issue>18</issue>
            <fpage>e009149</fpage>
            <pub-id pub-id-type="pmid">30371181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dauw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verbrugge</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Nijst</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meekers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tartaglia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chenot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moubayed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dierckx</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blouard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Troisfontaines</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Derthoo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smolders</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bruckers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Droogne</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ter Maaten</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Damman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lassus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>M</given-names>
              </name>
              <collab>ADVOR Study Group</collab>
            </person-group>
            <article-title>Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Sep</month>
            <day>29</day>
            <volume>387</volume>
            <issue>13</issue>
            <fpage>1185</fpage>
            <page-range>1185-1195</page-range>
            <pub-id pub-id-type="pmid">36027559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyakoshi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yaku</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inuzuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ozasa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WHW</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>e204296</fpage>
            <pub-id pub-id-type="pmid">32379331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>1025</fpage>
            <page-range>1025-9</page-range>
            <pub-id pub-id-type="pmid">15337214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schj&#x000f8;dt</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Johnsen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Str&#x000f6;mberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeVore</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Valentin</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>L&#x000f8;gstrup</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>e007973</fpage>
            <pub-id pub-id-type="pmid">35272503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brater</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with exacerbation of heart failure include treatment adherence and health literacy skills.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>651</fpage>
            <page-range>651-8</page-range>
            <pub-id pub-id-type="pmid">19262464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164817.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeWalt</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Schillinger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ruo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bibbins-Domingo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Macabasco-O'Connell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Broucksou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hawk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grady</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Erman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sueta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Cene</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pignone</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Multisite randomized trial of a single-session versus multisession literacy-sensitive self-care intervention for patients with heart failure.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Jun</month>
            <day>12</day>
            <volume>125</volume>
            <issue>23</issue>
            <fpage>2854</fpage>
            <page-range>2854-62</page-range>
            <pub-id pub-id-type="pmid">22572916</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
